Your browser doesn't support javascript.
loading
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman, Jad; Wilhelm-Benartzi, Charlotte; Dillon, Richard; Knapper, Steve; Freeman, Sylvie D; Batten, Leona M; Canham, Joanna; Hinson, Emily L; Wych, Julie; Betteridge, Sophie; Villiers, William; Kleeman, Michelle; Gilkes, Amanda; Potter, Nicola; Overgaard, Ulrik Malthe; Mehta, Priyanka; Kottaridis, Panagiotis; Cavenagh, Jamie; Hemmaway, Claire; Arnold, Claire; Dennis, Mike; Russell, Nigel H.
Afiliação
  • Othman J; Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom.
  • Wilhelm-Benartzi C; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Dillon R; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Knapper S; Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom.
  • Freeman SD; Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Batten LM; School of Medicine, Cardiff University, Cardiff, United Kingdom.
  • Canham J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Hinson EL; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Wych J; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Betteridge S; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Villiers W; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Kleeman M; Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
  • Gilkes A; Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom.
  • Potter N; Genomics Facility, NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
  • Overgaard UM; School of Medicine, Cardiff University, Cardiff, United Kingdom.
  • Mehta P; Department of Medical and Molecular Genetics, Kings College London, London, United Kingdom.
  • Kottaridis P; Copenhagen University Hospital, Copenhagen, Denmark.
  • Cavenagh J; Bristol Haematology and Oncology Centre, University Hospitals of Bristol and Weston NHS Trust, Bristol, United Kingdom.
  • Hemmaway C; Department of Haematology, University College Hospital, London, United Kingdom.
  • Arnold C; Department of Haemato-Oncology, Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom.
  • Dennis M; Department of Haematology, Auckland Hospital, Auckland, New Zealand.
  • Russell NH; Clinical Haematology, Belfast City Hospital, Belfast, Northern Ireland.
Blood Adv ; 7(16): 4539-4549, 2023 08 22.
Article em En | MEDLINE | ID: mdl-37171402
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mieloide Aguda Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article